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Hsp104 reduces dopaminergic cell loss in the substantia nigra of rats expressing human α-syn A30P. (A) Staining for TH at 6 weeks in the 
substantia nigra of rats injected with either lenti-A30P/lenti-YFP or lenti-A30P/lenti-Hsp104. (B) Quantitation of TH-IR nigral neurons at 6 weeks 
relative to the contralateral side in rats unilaterally injected with the different lentiviral constructs. Values represent mean ± SEM; n = 7 animals for 
both A30P/YFP and A30P/Hsp104 groups; P < 0.05. (C) Confocal imaging of triple labeling for TH (red), A30P human α-syn (blue), and Hsp104 
(green) in the rat substantia nigra injected with lenti-A30P/lenti-Hsp104. Higher magnification (bottom row) reveals numerous TH neurons posi-
tive for Hsp104 and A30P human α-syn at 6 weeks after injection. Scale bar: 350 μm (A and C, top row); 60 μm (C, bottom row).
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Hsp104 inhibits α-syn amyloidogenesis. From our in vivo experiments, 
it is difficult to distinguish whether Hsp104 prevents aggregation 
Figure 3
Hsp104 prevents A30P α-syn–induced neurode-
generation. (A–G) Degenerating nigral neurons 
were detected by silver staining. (A and D) Non-
injected sides did not show any specific silver 
staining. (D–G) Higher magnification reveals 
numerous silver-positive dark structures in the 
substantia nigra of animals expressing A30P/
YFP (E). (G) Abundant neuritic pathology clearly 
showed the presence of degenerating neurites. 
(C and F) Coexpression of Hsp104 with A30P 
α-syn prevents the appearance of silver-posi-
tive degenerating neurons. Scale bar: 300 μm 
(A–C); 100 μm (D–G).
Figure 2
Hsp104 reduces α-syn–induced dopaminergic fiber loss in the striatum 
of rats. (A) Striatal sections stained for TH from rats after intranigral injec-
tions of either lenti-A30P/lenti-YFP or lenti-A30P/lenti-Hsp104 (arrows 
indicate the injected sides). Original magnification, ×3. (B) Quantitation 
of the loss of TH fibers at 6 weeks, relative to the contralateral side in 
rats unilaterally injected with the different lentiviral vectors. Values rep-
resent mean ± SEM; n = 7 animals per group; P < 0.05.
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Hsp104 remodels α-syn A30P preamyloid oligomers.  Preamyloid 
oligomers may be the more cytotoxic species in many neurodegen-
Figure 4
Hsp104 reduces the number of phosphorylated 
α-syn inclusions. (A–C) Robust expression of human 
α-syn was detected with both RG syn and (D–I) the 
human specific LB509 Abs. (G–I) Higher magnification 
revealed the accumulation and aggregation of human 
α-syn in both the cell bodies (arrows) and neurites 
(arrowheads). (H and I) Note that there are fewer dense 
puncta in neurites in the A30P/Hsp104 condition. (J) 
Sections of the substantia nigra from the noninjected 
side and (K) from rats expressing A30P/YFP or (L) 
A30P/Hsp104 were immunostained with Ab specific for 
phosphorylated Ser 129 of α-syn. The substantia nigra 
of animals overexpressing either A30P/YFP or A30P/
Hsp104 reveals the presence of hyperphosphorylated 
inclusions reminiscent of Lewy bodies. Scale bar: 
300 μm (A–F); 40 μm (G–I); 50 μm (J–L). (M) Quan-
titation of neurons containing Pser129-positive aggre-
gates in the substantia nigra of rats expressing A30P/
YFP or A30P/Hsp104. Values represent mean ± SEM; 
n = 6 animals per group; P < 0.05.
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Hsp104 inhibits α-syn fibrillization. (A and B) Kinetics of rotated (80 rpm) α-syn (80 μM) fibrillization at 37°C without or with either Hsp104 
(0.2–1.6 μM) plus ATP and regeneration system (20 mM creatine phosphate and 0.1 mg/ml creatine kinase), Hsp104 (0.2 μM) with no nucleotide, 
Hsp104 (0.2 μM) plus nonhydrolyzable ATP analogue (AMP-PNP), or Hsp104K218T:K620T (0.2 μM) plus ATP and regeneration system. Fibrillization 
was measured by ThT fluorescence (A) or sedimentation analysis (B). Values represent mean ± SD; n = 3. (C) EM of α-syn (80 μM) fibrillization 
at 37°C for 48 hours without or with Hsp104 (1.6 μM) plus ATP and regeneration system. Scale bar: 200 nm. (D) α-syn (80 μM) was incubated 
for 96 hours with rotation at 37°C in the presence or absence of Hsp104 (1.6 μM) plus ATP and regeneration system. After 72 hours, reactions 
were either supplemented with buffer or fresh Hsp104 (1.6 μM). Fibrillization was measured by ThT fluorescence. Values represent mean ± SD; 
n = 3. (E) Fibrillization kinetics of wild-type, A53T, A30P, E46K, S129A, and S129E α-syn (80 μM) in the presence or absence of Hsp104 (2 μM) 
plus ATP and regeneration system. Another reaction contained A53T (80 μM) plus Hsp104 (4 μM) with ATP and regeneration system. Reactions 
were rotated (80 rpm) at 37°C. Fibrillization was measured by ThT fluorescence. Values represent mean ± SD; n = 4.
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Hsp104 remodels α-syn A30P preamyloid oligomers. (A–D) Purified α-syn A30P preamyloid oligomers (0.5 μM) were incubated without or with 
Hsp104 or Hsp104K218T:K620T (10 μM) plus ATP and regeneration system for 1 hour at 37°C. Reactions were spotted on nitrocellulose and probed 
with anti-oligomer Ab or anti–α-syn Ab (A). (B) Alternatively, reactions were processed for EM (scale bar: 25 nm) or (C) depleted of Hsp104 and 
passed through a 100-kDa molecular weight filter. (C and D) Retentate and filtrate fractions were collected and analyzed by SDS-PAGE, and 
the amount of A30P in the filtrate was determined by densitometry. Values represent mean ± SD; n = 4 (D).
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Hsp104 remodels α-syn fibers. (A and B) Fibers 
composed of wild-type, A53T, A30P, E46K, S129A, 
or S129E α-syn (0.5 mM monomer) were incu-
bated with Hsp104K218T:K620T, Hsp104 (10 μM) 
plus ATP and regeneration system, or AMP-PNP 
system for 1 hour at 37°C. Fiber integrity was 
determined by ThT fluorescence (A) or turbid-
ity (B). For each fiber, 100% assembly reflects 
untreated fibers. Values represent mean ± SD; 
n = 3. (C) EM of A30P fibers incubated without 
or with Hsp104 with ATP and regeneration sys-
tem as in A. Scale bar: 0.5 μm. (D and E) Fibers 
composed of wild-type α-syn (0.5 μM monomer) 
were incubated for 1 hour at 37°C without or with 
the indicated combinations of Hsp104 (10 μM), 
Hsp70 (10 μM), Hsc70 (10 μM), Hdj1 (10 μM), or 
Hdj2 (10 μM) plus ATP and regeneration system. 
Fiber integrity was determined by ThT fluores-
cence (D) or sedimentation analysis (E). Values 
represent mean ± SD; n = 3.
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Silver  staining was  performed  to  detect  degenerating  neurons  on 
paraformaldehyde-fixed sections (18, 47). The FD NeuroSilver kit was used 
according to the manufacturer’s protocol (FD Neuro-Technologies).
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